NZ531180A - Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide - Google Patents
Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptideInfo
- Publication number
- NZ531180A NZ531180A NZ531180A NZ53118000A NZ531180A NZ 531180 A NZ531180 A NZ 531180A NZ 531180 A NZ531180 A NZ 531180A NZ 53118000 A NZ53118000 A NZ 53118000A NZ 531180 A NZ531180 A NZ 531180A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lipg
- leu
- gly
- ser
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ531180A true NZ531180A (en) | 2005-06-24 |
Family
ID=23060703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ51435000A NZ514350A (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
NZ531180A NZ531180A (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ51435000A NZ514350A (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (fr) |
JP (1) | JP2002540127A (fr) |
KR (2) | KR100887164B1 (fr) |
AU (1) | AU776684B2 (fr) |
BR (1) | BR0009333A (fr) |
CA (1) | CA2363486C (fr) |
HK (1) | HK1043309A1 (fr) |
IL (2) | IL145526A0 (fr) |
MX (1) | MXPA01009727A (fr) |
NO (2) | NO331779B1 (fr) |
NZ (2) | NZ514350A (fr) |
WO (1) | WO2000057837A2 (fr) |
ZA (1) | ZA200107598B (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードrna転写物 |
JP6091752B2 (ja) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療 |
RU2618688C2 (ru) | 2008-12-04 | 2017-05-10 | КьюРНА,Инк.,US | Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена |
WO2010065671A2 (fr) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition de la transcription antisens naturelle en vegf |
HUE026280T2 (en) | 2009-02-12 | 2016-06-28 | Curna Inc | Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t |
US9464287B2 (en) | 2009-03-16 | 2016-10-11 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2 |
US9708604B2 (en) | 2009-03-17 | 2017-07-18 | Curna, Inc. | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 |
CN102803492B (zh) | 2009-05-06 | 2016-06-29 | 库尔纳公司 | 通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病 |
CA2761152A1 (fr) | 2009-05-06 | 2010-11-11 | Opko Curna, Llc | Traitement de maladies associees aux genes du metabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gene du metabolisme et du transport des lipides |
ES2618572T3 (es) | 2009-05-08 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd |
US8957037B2 (en) | 2009-05-18 | 2015-02-17 | Curna, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
JP2012527248A (ja) | 2009-05-22 | 2012-11-08 | クルナ・インコーポレーテッド | 転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置 |
KR101704988B1 (ko) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
EP2443237B1 (fr) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène |
CN102597238B (zh) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病 |
CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
EP2462229B1 (fr) | 2009-08-05 | 2016-05-11 | CuRNA, Inc. | Traitement de maladies liées à un gène de l insuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins) |
ES2599986T3 (es) | 2009-08-11 | 2017-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ) |
EP2982755B1 (fr) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Traitement de maladies associées à l'extrémité c terminale d'une protéine interagissant avec hsp70' (puce) par inhibition du transcrit antisens naturel de puce |
US9023822B2 (en) | 2009-08-25 | 2015-05-05 | Curna, Inc. | Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP |
CN102791861B (zh) | 2009-09-25 | 2018-08-07 | 库尔纳公司 | 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病 |
KR101823702B1 (ko) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | 막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료 |
KR101793753B1 (ko) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | 커플링방지 단백질 2(ucp2)에 대한 천연 안티센스 전사체의 저해에 의한 ucp2 관련 질환의 치료 |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
CN102770540B (zh) | 2009-12-29 | 2017-06-23 | 库尔纳公司 | 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病 |
RU2616283C2 (ru) | 2009-12-31 | 2017-04-13 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 |
RU2611187C2 (ru) | 2010-01-04 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8 |
CA2786056C (fr) | 2010-01-06 | 2023-03-14 | Curna, Inc. | Traitement de maladies associees a un gene de developpement pancreatique par inhibition du produit de la transcription anti-sens naturel en un gene de developpement pancreatique |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
ES2657969T3 (es) | 2010-04-02 | 2018-03-07 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3 |
CN102858979B (zh) | 2010-04-09 | 2018-01-26 | 库尔纳公司 | 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病 |
KR101936011B1 (ko) | 2010-05-03 | 2019-01-07 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP3299464B1 (fr) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Traitement de maladies associées à l'homologue atonal 1 par inhibition du produit de transcription antisens naturel d'atoh1 |
CN102971423B (zh) | 2010-05-26 | 2018-01-26 | 库尔纳公司 | 通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病 |
US9771579B2 (en) | 2010-06-23 | 2017-09-26 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA |
CA2805318A1 (fr) | 2010-07-14 | 2012-01-19 | Curna, Inc. | Traitement de maladies liees a « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療 |
WO2012068340A2 (fr) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Compositions d'antagonat et leurs méthodes d'utilisation |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
US9593330B2 (en) | 2011-06-09 | 2017-03-14 | Curna, Inc. | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN |
CA2847811C (fr) | 2011-09-06 | 2019-10-22 | Curna, Inc. | Traitement de maladies liees a des sous-unites alpha de canaux sodiques voltage-dependants (scnxa) avec de petites molecules |
KR20140136488A (ko) | 2012-03-15 | 2014-11-28 | 큐알엔에이, 인크. | 뇌 유래 신경영양 인자(bdnf)에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자(bdnf)관련 질환의 치료 |
CN102628060A (zh) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | 一种低脂奶的生产方法 |
US9695462B2 (en) | 2012-11-05 | 2017-07-04 | Shionogi & Co., Ltd. | Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity |
US9701757B2 (en) * | 2013-03-14 | 2017-07-11 | Shionogi & Co., Ltd. | Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
TWI688575B (zh) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
EP4284335A1 (fr) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Thérapie génique de céroïdes-lipofuscinoses neuronales |
EP4378480A1 (fr) * | 2021-07-26 | 2024-06-05 | Purotech Bio, Inc. | Agent anti-virus de l'hépatite b ciblant le facteur hôte lipg |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU679525B2 (en) * | 1992-12-04 | 1997-07-03 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
CN100497610C (zh) * | 1996-12-06 | 2009-06-10 | 阿温蒂斯药物公司 | 人脂酶样基因编码的多肽及利用它的组合物和方法 |
WO1999032611A1 (fr) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | Lipase exprimee dans des cellules endotheliales et procedes d'utilisation associes |
-
2000
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/es active IP Right Grant
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/pt not_active Application Discontinuation
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/ko not_active IP Right Cessation
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/xx not_active IP Right Cessation
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/ja active Pending
- 2000-03-24 EP EP00918362A patent/EP1171078A4/fr not_active Ceased
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/ko active Search and Examination
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/fr active IP Right Grant
- 2000-03-24 IL IL14552600A patent/IL145526A0/xx unknown
- 2000-03-24 CA CA2363486A patent/CA2363486C/fr not_active Expired - Fee Related
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/xx unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/no not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/zh unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1171078A2 (fr) | 2002-01-16 |
NO331779B1 (no) | 2012-03-26 |
MXPA01009727A (es) | 2002-07-22 |
KR20020029651A (ko) | 2002-04-19 |
WO2000057837A2 (fr) | 2000-10-05 |
WO2000057837A8 (fr) | 2001-09-27 |
ZA200107598B (en) | 2003-05-28 |
IL145526A0 (en) | 2002-06-30 |
KR20050044812A (ko) | 2005-05-12 |
NO331784B1 (no) | 2012-03-26 |
IL145526A (en) | 2010-11-30 |
AU776684B2 (en) | 2004-09-16 |
CA2363486A1 (fr) | 2000-10-05 |
NO20014657L (no) | 2001-11-21 |
NO20014657D0 (no) | 2001-09-25 |
BR0009333A (pt) | 2002-01-08 |
NO20100214L (no) | 2001-11-21 |
KR100887164B1 (ko) | 2009-03-10 |
WO2000057837A3 (fr) | 2001-01-25 |
NZ514350A (en) | 2004-12-24 |
EP1171078A4 (fr) | 2002-11-06 |
HK1043309A1 (zh) | 2002-09-13 |
WO2000057837A9 (fr) | 2001-10-18 |
CA2363486C (fr) | 2012-12-18 |
JP2002540127A (ja) | 2002-11-26 |
AU3918700A (en) | 2000-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU776684B2 (en) | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol | |
US7008776B1 (en) | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol | |
US8343494B2 (en) | Antibodies against LLG polypeptides of the triacylglycerol lipase family | |
WO1998024888A9 (fr) | Polypeptides llg de la famille des triacylglycerol lipases, compositions et procedes destines a l'utilisation de ceux-ci dans des hydrolyses enzymatiques, et therapies geniques et protidiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Change of ownership |
Owner name: AVENTIS PHARMACEUTICALS INC, US Free format text: OLD OWNER(S): AVENTIS PHARMACEUTICALS INC.; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
|
PSEA | Patent sealed | ||
S35A | Application for proceedings under section 35 (restoration of lapsed patents) | ||
RENW | Renewal (renewal fees accepted) | ||
S35R | Proceedings under section 35 (restoration of lapsed patents): patent restored | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 24 MAR 2020 BY CPA GLOBAL Effective date: 20130211 |
|
EXPY | Patent expired |